June 4th 2025
A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.
IMDC Model Valid in First-Line Pazopanib for mRCC
December 22nd 2015A new study has confirmed the safety and efficacy of pazopanib in a real-world setting of patients with metastatic renal cell carcinoma (mRCC) and validates the International Metastatic Renal Cell Carcinoma Database (IMDC) prognostic model in this patient population.
Prophylaxis Fails to Prevent Thromboembolism After Partial Nephrectomy
December 21st 2015Administering pharmacological prophylaxis against venous thromboembolism (VTE) did not decrease the occurrence of VTE in patients treated with robotic partial nephrectomy, and it did not increase the rate of hemorrhagic events.
A Patient With Newly Diagnosed Metastatic Type 2 Papillary Renal Cell Carcinoma
A 42-year-old man presented with increasing right hip pain that limited his ability to walk. Magnetic resonance imaging (MRI) revealed a right lytic acetabular lesion. Further work-up included a computed tomography (CT) scan, which revealed an 8-cm left kidney tumor.
Renal Cancer Management in a Patient With Chronic Kidney Disease
A 69-year-old man presented in the urology clinic for evaluation of bilateral renal masses, discovered incidentally during routine exams for follow-up of his chronic kidney disease.